Both SPOP mutation [61] and CDC20 overexpression are important in docetaxel resistance with the inhibition or knockdown of CDC20 being able to resensitise cells to docetaxel [62] highlighting the importance of CDC20 as a therapeutic target in prostate cancer at several disease stages. This evidence concerns the gene SPOP and prostate carcinoma.